Health Trials

Transformed Follicular Lymphoma (TFL)

3

Review clinical trials related to Transformed Follicular Lymphoma (TFL). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients

This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma and B-cell Acute Lymphoblastic Leukemia.

Participants needed: 91
Trial details
Phase: Phase 1, Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: Curocell Inc.Updated: Jul 1, 2026Locations: 2
Eligibility criteria

≥ 19 years of age and provided written informed consent [+24]

Patients with the following medical history [+72]

Read more
Status: Not yet recruiting

A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies

This is an investigator-initiated, open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of MTM-H-001 in adult participants with relapsed/refractory (R/R) B-cell malignancies.

Participants needed: 69
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesUpdated: Mar 17, 2026Locations: 1
Eligibility criteria

Male or female, aged 18 - 75 years old (inclusive); [+12]

B-NHL participants with a history of Richter's transformation of chronic lymphoc... [+15]

Read more
Status: Recruiting

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

This is a multi-center, phase I/II study to determine the safety and efficacy of TC011(CD19 Targeted CAR-T) in adult patients with relapsed or refractory large B-cell non -hodgkin lymphoma.

Participants needed: 98
Trial details
Phase: Phase 1, Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: TICAROS Co., Ltd.Updated: Mar 16, 2026Locations: 1
Eligibility criteria

≥19 years old, ECOG 0-2, life expectancy ≥12 weeks [+7]

Unresolved ≥Grade 2 toxicities from prior therapy [+12]

Read more